Vaxcyte, Inc. (NASDAQ:PCVX) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 3,770,000 shares, a decrease of 21.1% from the March 31st total of 4,780,000 shares. Based on an average trading volume of 419,100 shares, the short-interest ratio is presently 9.0 days. Approximately 13.3% of the company’s shares are sold short.
Separately, Zacks Investment Research lowered shares of Vaxcyte from a “hold” rating to a “sell” rating in a research report on Friday, April 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Vaxcyte has an average rating of “Buy” and an average price target of $48.00.
Shares of NASDAQ PCVX traded down $1.21 during mid-day trading on Tuesday, reaching $17.28. The company’s stock had a trading volume of 178,349 shares, compared to its average volume of 382,115. The stock has a fifty day moving average of $21.11 and a two-hundred day moving average of $27.91. Vaxcyte has a 52 week low of $17.02 and a 52 week high of $58.47.
In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction dated Friday, March 19th. The shares were sold at an average price of $25.77, for a total value of $386,550.00. Following the completion of the transaction, the chief executive officer now directly owns 593,691 shares of the company’s stock, valued at $15,299,417.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert Lorne Hopfner sold 79,796 shares of the company’s stock in a transaction on Monday, February 8th. The shares were sold at an average price of $25.79, for a total value of $2,057,938.84. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 184,954 shares of company stock valued at $4,811,743.
Several large investors have recently bought and sold shares of the stock. Penserra Capital Management LLC purchased a new position in Vaxcyte during the 4th quarter valued at approximately $31,000. Pacer Advisors Inc. bought a new stake in Vaxcyte in the fourth quarter worth $34,000. Morgan Stanley raised its stake in Vaxcyte by 2,859.0% during the third quarter. Morgan Stanley now owns 2,959 shares of the company’s stock valued at $146,000 after purchasing an additional 2,859 shares in the last quarter. Strs Ohio bought a new position in Vaxcyte during the third quarter valued at $227,000. Finally, Citigroup Inc. grew its position in Vaxcyte by 503.0% in the fourth quarter. Citigroup Inc. now owns 5,270 shares of the company’s stock worth $140,000 after acquiring an additional 4,396 shares in the last quarter. Institutional investors own 74.08% of the company’s stock.
Vaxcyte, Inc, a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis.
Read More: The limitations of an equal weight rating
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.